Fiala O - Search Results

1

Giant Cell Temporal Arteritis Followed by Severe Encephalopathy Induced by Immunotherapy in a Patient with Metastatic Renal Cell Carcinoma Achieving Durable Partial Response: A Case Report.

Fiala O, Tkadlecová M, Pivovarčíková K, Baxa J, Stránský P, Šiková D, Hora M, Fínek J. Fiala O, et al. Case Rep Oncol. 2024 Aug 26;17(1):921-927. doi: 10.1159/000540660. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 39474545 Free PMC article.

2

The role of cetuximab in the treatment of metastatic colorectal cancer.

Holubec L, Liska V, Matejka VM, Fiala O, Dreslerova J, Mrazkova P, Treska V, Finek J. Holubec L, et al. Among authors: fiala o. Anticancer Res. 2012 Sep;32(9):4007-11. Anticancer Res. 2012. PMID: 22993351 Review.

3

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.

Fiala O, Pesek M, Finek J, Krejci J, Ricar J, Bortlicek Z, Benesova L, Minarik M. Fiala O, et al. Neoplasma. 2013;60(1):26-32. doi: 10.4149/neo_2013_004. Neoplasma. 2013. PMID: 23067213

4

Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.

Fiala O, Pesek M, Finek J, Krejci J, Bortlicek Z, Benesova L, Minarik M. Fiala O, et al. Neoplasma. 2013;60(2):129-34. doi: 10.4149/neo_2013_017. Neoplasma. 2013. PMID: 23259780

5

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. Fiala O, et al. Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10. Cancer Genet. 2013. PMID: 23313110

6

Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M. Fiala O, et al. Anticancer Res. 2013 Apr;33(4):1705-11. Anticancer Res. 2013. PMID: 23564819

7

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M. Fiala O, et al. Neoplasma. 2013;60(4):425-31. doi: 10.4149/neo_2013_055. Neoplasma. 2013. PMID: 23581415

8

Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M. Fiala O, et al. Anticancer Res. 2013 Aug;33(8):3397-402. Anticancer Res. 2013. PMID: 23898110

9

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O. Fiala O, et al. Anticancer Res. 2014 Jun;34(6):3205-10. Anticancer Res. 2014. PMID: 24922695

10

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.

Fiala O, Pesek M, Finek J, Krakorova G, Benesova L, Minarik M. Fiala O, et al. Tumori. 2014 May-Jun;100(3):e70-3. doi: 10.1700/1578.17234. Tumori. 2014. PMID: 25076254

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters